{"id":2275,"date":"2017-08-25T10:22:25","date_gmt":"2017-08-25T04:52:25","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2275"},"modified":"2021-07-24T12:56:49","modified_gmt":"2021-07-24T07:26:49","slug":"the-business-cocktail-33","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-33","title":{"rendered":"Can-Fite Receives Payment; Leafbuyer Technologies and Denver Post\u2019s Cannabist; EPX-300 &#038; JOTROL received Designation; New treatment Approved for adults"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a01b8ad26680\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a01b8ad26680\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-33\/#Can-Fite_Receives_Milestone_Payment_from_Korean_Distribution_Partner_CKD_Pharmaceuticals\" >Can-Fite Receives Milestone Payment from Korean Distribution Partner CKD Pharmaceuticals<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-33\/#Leafbuyer_Technologies_and_Denver_Posts_Cannabist_have_renewed_their_partnership\" >Leafbuyer Technologies and Denver Post\u2019s Cannabist have renewed their partnership<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-33\/#EPX-300_of_Epygenix_Therapeutics_and_JOTROL_of_Jupiter_has_received_Orphan_Drug_Designation_for_the_treatment_of_Dravet_Syndrome_and_Friedreichs_Ataxia_respectively\" >EPX-300 of Epygenix Therapeutics and JOTROL of Jupiter has received Orphan Drug Designation for the treatment of Dravet Syndrome and Friedreich&#8217;s Ataxia respectively.<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-33\/#New_treatment_Approved_for_adults_with_relapsed_or_refractory_acute_lymphoblastic_leukemia_by_the_USFDA\" >New treatment Approved for adults with relapsed or refractory acute lymphoblastic leukemia by the USFDA<\/a><\/li><\/ul><\/nav><\/div>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Can-Fite_Receives_Milestone_Payment_from_Korean_Distribution_Partner_CKD_Pharmaceuticals\"><\/span>Can-Fite Receives Milestone Payment from Korean Distribution Partner CKD Pharmaceuticals<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Can-Fite BioPharma Ltd., A Leading Biotechnology Company in the pharmaceutical industry advancing a pipeline of proprietary drugs that address various major indications related to liver, inflammatory diseases, and cancer, has announced that it has received a milestone payment in the amount of $500,000 from Chong Kun Dang Pharmaceuticals the Korean distribution partner of Can-Fite BioPharma. This milestone payment is the second one, which is for completing patient enrollment in Europe, Israel and US for Phase II trials in advanced hepatocellular carcinoma. The trial will aim to assess the safety and efficacy of Namodenoson (CF102). Can-Fite has exclusive license to distribute this drug, which is being developed by CKD Pharmaceuticals.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"Leafbuyer_Technologies_and_Denver_Posts_Cannabist_have_renewed_their_partnership\"><\/span>Leafbuyer Technologies and Denver Post\u2019s Cannabist have renewed their partnership<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Leafbuyer Technologies, Inc.,\u00a0a leading cannabis technology company has announced that it has renewed its partnership with the\u00a0Cannabist. Cannabist is a marijuana news website, and this renewal will continue their partnership of expanding consumer base of Leafbuyer and increase their brand identity. LeafBuyer Technologies CEO expects that 2018 will be a watershed year in this industry and they will grow with the Cannabist. The two companies already have a strong base in Colorado, and expect their presence to grow in Washington, Oregon, California, Arizona, Nevada and Michigan through this partnership.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"EPX-300_of_Epygenix_Therapeutics_and_JOTROL_of_Jupiter_has_received_Orphan_Drug_Designation_for_the_treatment_of_Dravet_Syndrome_and_Friedreichs_Ataxia_respectively\"><\/span>EPX-300 of Epygenix Therapeutics and JOTROL of Jupiter has received Orphan Drug Designation for the treatment of Dravet Syndrome and Friedreich&#8217;s Ataxia respectively.<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">Epygenix Therapeutics, Inc., a privately held biopharmaceutical company developing precision medicine for catastrophic and rare forms of genetic epilepsy, has announced that the USFDA has granted Orphan Drug Designation for their drug EPX-300 for the treatment of patients with Dravet Syndrome. Additionally, Jupiter Orphan Therapeutics has also announced that they have received notification from the USFDA that its Orphan Drug Designation request for Trans-Resveratrol Product JOTROL for Treatment of Friedreich&#8217;s Ataxia has been granted.<\/p>\n<h3 style=\"text-align: justify;\"><span class=\"ez-toc-section\" id=\"New_treatment_Approved_for_adults_with_relapsed_or_refractory_acute_lymphoblastic_leukemia_by_the_USFDA\"><\/span>New treatment Approved for adults with relapsed or refractory acute lymphoblastic leukemia by the USFDA<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p style=\"text-align: justify;\">The USFDA has approved Pfizer\u2019s Besponsa (inotuzumab ozogamicin) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults through a Priority Review and Breakthrough Therapy Designations. Besponsa is a targeted therapy that is thought to work by binding to B-cell ALL cancer cells that express the CD22 antigen, blocking the growth of cancerous cells. The approval is based on the clinical trial results carried out to check for the safety and efficacy of this drug in 326 adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia. Besponsa has also received Orphan Drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Can-Fite Receives Milestone Payment from Korean Distribution Partner CKD Pharmaceuticals Can-Fite BioPharma Ltd., A Leading Biotechnology Company in the pharmaceutical industry advancing a pipeline of proprietary drugs that address various major indications related to liver, inflammatory diseases, and cancer, has announced that it has received a milestone payment in the amount of $500,000 from Chong [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1040,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[17564,12079,997,137,998,996,460],"industry":[17225],"therapeutic_areas":[17238,17227,17228,17234],"class_list":["post-2275","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-acute-lymphoblastic-leukemia","tag-all","tag-can-fite","tag-cancer","tag-cannabist","tag-ckd-pharma","tag-pfizer","industry-pharmaceutical","therapeutic_areas-genetic-disorders","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-oncology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Can-Fite Receives Payment; Leafbuyer Technologies and Denver Post<\/title>\n<meta name=\"description\" content=\"Can-Fite BioPharma Ltd., A Leading Biotechnology Company in the pharmaceutical industry advancing a pipeline of proprietary drugs that address....\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-33\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Can-Fite Receives Payment; Leafbuyer Technologies and Denver Post\" \/>\n<meta property=\"og:description\" content=\"Can-Fite BioPharma Ltd., A Leading Biotechnology Company in the pharmaceutical industry advancing a pipeline of proprietary drugs that address....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-33\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-08-25T04:52:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021458\/chess_board_glass_black_white_surface_15259_602x339.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"602\" \/>\n\t<meta property=\"og:image:height\" content=\"339\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Can-Fite Receives Payment; Leafbuyer Technologies and Denver Post","description":"Can-Fite BioPharma Ltd., A Leading Biotechnology Company in the pharmaceutical industry advancing a pipeline of proprietary drugs that address....","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-33","og_locale":"en_US","og_type":"article","og_title":"Can-Fite Receives Payment; Leafbuyer Technologies and Denver Post","og_description":"Can-Fite BioPharma Ltd., A Leading Biotechnology Company in the pharmaceutical industry advancing a pipeline of proprietary drugs that address....","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-33","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-08-25T04:52:25+00:00","article_modified_time":"2021-07-24T07:26:49+00:00","og_image":[{"width":602,"height":339,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021458\/chess_board_glass_black_white_surface_15259_602x339.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-33","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-33","name":"Can-Fite Receives Payment; Leafbuyer Technologies and Denver Post","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-33#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-33#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021458\/chess_board_glass_black_white_surface_15259_602x339.jpg","datePublished":"2017-08-25T04:52:25+00:00","dateModified":"2021-07-24T07:26:49+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Can-Fite BioPharma Ltd., A Leading Biotechnology Company in the pharmaceutical industry advancing a pipeline of proprietary drugs that address....","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-33"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-33#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021458\/chess_board_glass_black_white_surface_15259_602x339.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021458\/chess_board_glass_black_white_surface_15259_602x339.jpg","width":602,"height":339},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/08\/09021458\/chess_board_glass_black_white_surface_15259_602x339-300x169.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Acute Lymphoblastic Leukemia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">ALL<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Can-Fite<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cannabist<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CKD Pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Acute Lymphoblastic Leukemia<\/span>","<span class=\"advgb-post-tax-term\">ALL<\/span>","<span class=\"advgb-post-tax-term\">Can-Fite<\/span>","<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">Cannabist<\/span>","<span class=\"advgb-post-tax-term\">CKD Pharma<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Aug 25, 2017","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Aug 25, 2017 10:22 am","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2275","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2275"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2275\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1040"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2275"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2275"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2275"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2275"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2275"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}